Skip to content

Public FDA record

Z-2301-2020: Histoplasma Immunodiffusion (ID) Antigen; The IFU labeling is for multiple products which included Fungal

Recall record Z-2301-2020 for Immuno-Mycologics, Inc. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2301-2020
Company in FDA record
Immuno-Mycologics, Inc
FDA record creation date
Jun 9, 2020
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

False positive results due to potential contamination of reagent.

Source facts

Action
On November 04, 2019, the firm sent out an urgent medical device recall notification to customers via e-mail of voluntary recall of an antigen, due to false positive results. The antigen was distributed to customers between September 4, 2019 and October 14, 2019. 1 complaint associated with this issue was reported. There have been no reports of patient injury or death. Risk to Health: The firm reported that in the case of false-positives, clinicians who use immuno-diffusion (ID) results alone may unnecessarily treat patients. The results of any sample that ran negative using this lot of antigen should NOT be affected. In other words, the negative predictive value of this lot has not changed from previous lots. If the test is interpreted without considering other clinical evidence, it is not possible to tell if a positive result is a true positive or a false positive. The firm notified customers to : Immediately check inventory and destroy the antigen and immediately complete the attached Acknowledgement and Receipt Form and attach it to an email and send the completed form to manufacturer using Email or mail to: Joy Pelfrey IMMY 2701 Corporate Centre Dr Norman, OK 73069 Additionally, the firm instructed customers to inform staff members of this recall, including to relevant clinicians, any other organization and display the recall notice. The customers can request a free-of-charge replacement. The actions being taken by the recalling firm is that they are immediately removing all material from the market and will be investigating the source for false-positive results. The firm will take mitigation actions.
Initiated
2019-11-04
Root cause
Under Investigation by firm
Terminated
2022-05-27
Distribution
Worldwide distribution - US Nationwide distribution including in the states of AZ, CA, FL, IL, IN, MI, MN, NY,TX, UT, VA, WI and the countries of France, Spain, Hong Kong, United Kingdom.
Recall number
Z-2301-2020
Recall status
Terminated
CDRH record ID
180696
FDA record created
2020-06-09
Recall event number
85368

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗